The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Olanzapine/Samidorphan Maintains Mood Disorder Efficacy, Weight and Glycemic Tolerability at 4 Years
May 4th 2024Four-year, phase 3 data from APA 2024 show olanzapine/samidorphan provided consistent antipsychotic efficacy and weight-related safety in patients with either schizophrenia or bipolar I disorder.